Agency classClass IIOur severity:Severe FDA (Drugs)·D-0026-2027·Announced 2026-10-14

Carolina Infusion Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns

Carolina Infusion, LLC is recalling semaglutide/cyanocobalamin injectable products due to a lack of assurance of sterility related to formulation and processing equipment.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as Class II due to a lack of assurance of sterility in the compounded injectable product. The source does not report any illnesses, injuries, or deaths.

Plain-English summary

Carolina Infusion, LLC is recalling semaglutide/cyanocobalamin 9/2 mg/ml injectable products. The recall is due to a lack of assurance of sterility, which is related to the use of bacteriostic water in the formulation and the processing equipment used in the compounded product.

The affected products are packaged in single-use dosage syringes, with the total milliliters dispensed based on specific patient prescriptions. The recall covers lots 07242026@1, 08032026@20, 08312026@16, 08242026@28, and 08072026@16, with expiration dates ranging from September 7, 2026, to October 15, 2026. The products were distributed nationwide within the United States.

Patients who have received these products should contact their healthcare provider for guidance. The source text does not report any illnesses, injuries, or deaths associated with this recall.

The recalled product

Product: SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Manufacturer: Carolina Infusion, LLC
Category: Drug — Compounded Injectable
Hazard: sterility
contamination

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (10)

Lot: 07242026@1
BUD: 9/7/2026
08032026@20
BUD: 9/17/2026
08312026@16
BUD: 10/15/2026
08242026@28
BUD: 10/8/2026
08072026@16
BUD: 9/21/2026. .

Distribution

Distributed nationwide across the United States.

Same manufacturer · Carolina Infusion, LLC

See all →

Severe
FDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Severe
FDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Severe
Carolina Infusion Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Severe
Carolina Infusion Recalls Semaglutide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
Severe
FDA Recalls Tri-MIX Syringes Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-10-14

Same hazard · sterility